Brief: AB Science: Health Canada Has Resumed Review Of New Drug Submission For Masitinib
09/05/2023 17:13
May 9 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMED ITS
REVIEW
OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL
SCLEROSIS, FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE LETTER
* UNDER NOC/C POLICY, HEALTH CANADA HAS A TARGET OF 200
CALENDAR
DAYS MAXIMUM TO REVIEW APPLICATION
Source text for Eikon: ID:nGNE6QHCZF
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041